相关实验视频
Updated: Mar 6, 2026

05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
1.4K
关于使用GRADE方法对美国超重或肥胖成年人药物管理的联合TOS/OMA/OAC专家指导声明
Lydia Alexander1, Jonathan Q Purnell2, Karlijn Burridge3
1Enara Health, Inc., San Mateo, California, USA.
Obesity (Silver Spring, Md.)
|March 5, 2026
概括
有效的肥胖药物可用,但由于障碍,其使用不足. 更新的指南建议特定的FDA批准的药物用于慢性肥胖管理和体重维持.
科学领域:
- 肥胖医学 肥胖医学
- 临床实践指南 临床实践指南
- 药物治疗 药物治疗
背景情况:
- 肥胖影响超过40%的美国成年人,严重的肥胖症正在增加.
- 肥胖是一种慢性疾病,但其诊断和治疗不足.
- 对基于证据的肥胖治疗的有限访问加剧了严重程度和并发症.
研究的目的:
- 为肥胖症治疗制定最新的,基于证据的指导方针.
- 为使用FDA批准的肥胖药物提供建议.
- 解决限制获得有效肥胖护理的障碍.
主要方法:
- 一个由TOS,OMA和OAC召开的多学科小组.
- 使用推评估,开发和评价 (GRADE) 的分级方法.
- 进行了系统的证据综合和共识研讨会.
主要成果:
- 发布了关于FDA批准的8种肥胖药物的建议.
- 强烈建议使用布洛普-纳尔特雷克松,塞马格卢提德,蒂尔泽帕提德和塞特梅拉诺提德.
- 强烈建议在体重维持期间继续服用肥胖药物.
结论:
- 肥胖需要全面的,长期的,以人为中心的护理.
- 有效的肥胖药物由于系统性障碍而未得到充分利用.
- 扩大获取,减少耻辱感,确保公平覆盖至关重要.
相关概念视频
Drug Dosing: Obese Patients
320
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
320
Atherosclerosis III: Management
532
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
532
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
331
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
331
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
259
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
259
Diabetes: Management and Pharmacotherapy
1.2K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.2K
Hypertension IV: Drug Therapy and Lifestyle Modifications
797
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
797

